Study of Early Lymphopheresis for Relapsed/Refractory DLBCL Sheds Light on CAR-T Efficacy
Researchers explored early lymphopheresis for CD19-based chimeric antigen receptor T-cell therapy for relapsed/refractory DLBCL.
Researchers explored early lymphopheresis for CD19-based chimeric antigen receptor T-cell therapy for relapsed/refractory DLBCL.
Researchers sought to determine whether CAR-T therapy would be a viable option for patients with relapsed/refractory large B-cell lymphoma.
Significantly increased risk seen for any HPV-associated subsequent malignant neoplasms and oropharyngeal neoplasms.
Researchers sought to determine whether combining nivolumab plus brentuximab vedotin would improve response rates in CAYAs with Hodgkin lymphoma.
Researchers sought to determine whether lenalidomide maintenance would improve outcomes in patients with high-risk non-Hodgkin lymphoma who receive HDT/ASCT .
Research has suggested that ART may increase the risk of pediatric cancers, but studies have shown conflicting results, and questions remain.
Researchers sought to determine physician preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma in the third line setting.
Researchers sought to determine the role of certain genetic variants as biomarkers in primary central nervous system lymphoma.
From 15 to 40 years after diagnosis, pediatric cancer survivors have a roughly 4-fold higher risk of death than the general population, a study suggests.
Pembrolizumab plus ICE chemotherapy appears effective as second-line treatment in patients with transplant-eligible Hodgkin lymphoma.